22 September 2025 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 ...

C4X Discovery Holdings plc (LON:C4XD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. C4X Discovery Holdings plc operates as drug ...

LONDON (Reuters) - Britain's C4X Discovery said on Tuesday it was confident of striking partnership deals for its programmers in therapy areas such as sickle cell, cancer and inflammation, sending the ...

UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of exiting the exchange. Redx ...

22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug discovery company, today provides an update on the business following its delisting from AIM earlier in the year. Clive Dix, Executive ...

April 12 (Reuters) - Drug developer C4X Discovery C4XD.L said on Monday it has signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi SASY.PA ...

Indivior has paid 15.95 million pounds sterling ($20.4 million) to C4X Discovery for the full rights to the British biotech’s orexin-1 receptor antagonist being developed for substance use disorder.

LONDON (Reuters) -Drug developer C4X Discovery said on Monday it had signed an exclusive licensing deal worth up to 414 million euros ($492.12 million) with French drugmaker Sanofi to develop an oral ...